1. Home
  2. CGON vs CWK Comparison

CGON vs CWK Comparison

Compare CGON & CWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • CWK
  • Stock Information
  • Founded
  • CGON 2010
  • CWK 1784
  • Country
  • CGON United States
  • CWK United States
  • Employees
  • CGON N/A
  • CWK N/A
  • Industry
  • CGON
  • CWK Real Estate
  • Sector
  • CGON
  • CWK Finance
  • Exchange
  • CGON NYSE
  • CWK Nasdaq
  • Market Cap
  • CGON 2.1B
  • CWK 1.9B
  • IPO Year
  • CGON 2024
  • CWK 2018
  • Fundamental
  • Price
  • CGON $25.55
  • CWK $10.48
  • Analyst Decision
  • CGON Strong Buy
  • CWK Hold
  • Analyst Count
  • CGON 10
  • CWK 7
  • Target Price
  • CGON $64.44
  • CWK $13.00
  • AVG Volume (30 Days)
  • CGON 784.3K
  • CWK 1.5M
  • Earning Date
  • CGON 08-07-2025
  • CWK 07-28-2025
  • Dividend Yield
  • CGON N/A
  • CWK N/A
  • EPS Growth
  • CGON N/A
  • CWK 1337.16
  • EPS
  • CGON N/A
  • CWK 0.69
  • Revenue
  • CGON $662,000.00
  • CWK $9,546,300,000.00
  • Revenue This Year
  • CGON N/A
  • CWK $5.77
  • Revenue Next Year
  • CGON $14,719.70
  • CWK $5.65
  • P/E Ratio
  • CGON N/A
  • CWK $15.20
  • Revenue Growth
  • CGON 224.51
  • CWK 1.24
  • 52 Week Low
  • CGON $14.80
  • CWK $7.64
  • 52 Week High
  • CGON $40.47
  • CWK $16.11
  • Technical
  • Relative Strength Index (RSI)
  • CGON 48.31
  • CWK 54.57
  • Support Level
  • CGON $25.02
  • CWK $10.14
  • Resistance Level
  • CGON $26.97
  • CWK $10.71
  • Average True Range (ATR)
  • CGON 1.14
  • CWK 0.30
  • MACD
  • CGON -0.18
  • CWK -0.01
  • Stochastic Oscillator
  • CGON 17.79
  • CWK 59.70

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About CWK Cushman & Wakefield plc

Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.

Share on Social Networks: